Eterna TherapeuticsERNA
ERNA
About: Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.
Employees: 6
0
Funds holding %
of 7,310 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
13% more funds holding
Funds holding: 24 [Q4 2024] → 27 (+3) [Q1 2025]
0.91% more ownership
Funds ownership: 1.94% [Q4 2024] → 2.85% (+0.91%) [Q1 2025]
10% less capital invested
Capital invested by funds: $292K [Q4 2024] → $264K (-$28.2K) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for ERNA.
Financial journalist opinion
Based on 3 articles about ERNA published over the past 30 days
Neutral
GlobeNewsWire
6 days ago
Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development
Addition of Dr. Amir Jazaeri and Dr. Anna Jonsson Reflects Ernexa's Strategic Focus on Ovarian Cancer and Autoimmune Disease Programs Addition of Dr. Amir Jazaeri and Dr. Anna Jonsson Reflects Ernexa's Strategic Focus on Ovarian Cancer and Autoimmune Disease Programs
Neutral
GlobeNewsWire
1 week ago
Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement
Stockholder-approved financing brings total gross proceeds to $7.1 million; funds to support working capital initiatives Stockholder-approved financing brings total gross proceeds to $7.1 million; funds to support working capital initiatives
Neutral
GlobeNewsWire
3 weeks ago
Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split
CAMBRIDGE, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced a reverse stock split of its issued and outstanding shares of common stock, par value $0.005 per share (the “Common Stock”), at a ratio of 1-for-15, effective June 12, 2025 at 12:01 a.m. Eastern Time. The Company's Common Stock is expected to begin trading on a split-adjusted basis when the market opens on June 12, 2025, under the existing trading symbol “ERNA.”
Neutral
GlobeNewsWire
1 month ago
Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025
New data finds novel cell therapy successfully converts “cold” ovarian tumors into “hot,” demonstrating potential to unlock immune response and improve outcomes New data finds novel cell therapy successfully converts “cold” ovarian tumors into “hot,” demonstrating potential to unlock immune response and improve outcomes
Neutral
GlobeNewsWire
1 month ago
Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations
CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the formation of ErnexaTX2, a wholly owned subsidiary based in Texas.
Neutral
Newsfile Corp
1 month ago
Ernexa Therapeutics Announces Participation in the D. Boral Capital Inaugural Global Conference
Cambridge, Massachusetts--(Newsfile Corp. - May 8, 2025) - Ernexa Therapeutics (NASDAQ: ERNA), today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May 14, 2025, at The Plaza Hotel in New York City.
Neutral
GlobeNewsWire
2 months ago
Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025
CAMBRIDGE, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, presented noteworthy new data at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago on April 28.
Neutral
GlobeNewsWire
2 months ago
Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025
Conference attendees will get first look at new data that supports the potential of ERNA-101 to boost anti-tumor immunity in ovarian cancer Conference attendees will get first look at new data that supports the potential of ERNA-101 to boost anti-tumor immunity in ovarian cancer
Neutral
GlobeNewsWire
2 months ago
Ernexa Therapeutics Closes New Funding Round
Comes on the heels of company's rebranding and new strategic direction, advancing its lead program in ovarian cancer Comes on the heels of company's rebranding and new strategic direction, advancing its lead program in ovarian cancer
Neutral
GlobeNewsWire
4 months ago
Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline
Meeting addressed progress and strategic direction for company's induced mesenchymal stem cell (iMSC) therapy programs Meeting addressed progress and strategic direction for company's induced mesenchymal stem cell (iMSC) therapy programs
Charts implemented using Lightweight Charts™